SLC6A3
ENSG00000142319
Target class
Transporter
Chromosome
5
Approved drugs
26
Clinical candidates (approved and in development)
35
- Approved drugs
- 26
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 35
- Chemical probe available
- Yes
- Other names
- DAT
- Target name
- SLC6A3
- Gene name
- Solute carrier family 6 member 3
- Gene symbol
- SLC6A3
- Previous gene symbols
- DAT1
- Protein name
- Sodium-dependent dopamine transporter (DA transporter) (DAT) (Solute carrier family 6 member 3)
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 6
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 34.67
- Tissue specificity (Gini)
- 0.879
- Tissue specificity (tau)
- 0.993
- KEGG gene identifiers
- hsa:6531
- Protein interaction confidence
- 0.850756
- Protein interaction partners
- 41
- R-HSA-379401
- R-HSA-442660
- R-HSA-5619081
- R-HSA-5660724
- End position
- 1445514
- Start position
- 1392794
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Cell projection, neuron projection . Cell projection, axon . Note=Localizes to neurite tips in neuronal cells (By similarity). Colocalizes with SEPTIN4 at axon terminals, especially at the varicosities (By similarity). .
- Vesicles
- PubMed 11343649
- PubMed 15505207
- PubMed 39112701
- PubMed 39112703
- PubMed 39112705
- PubMed 17296554
- Tissue specificity (tau)
- 0.99274
- Expression inequality (Gini)
- 0.87881
Expression in transcripts per million
- Brain - Substantia nigra
- 34.67
- Thyroid
- 1.81
- Ovary
- 1.07
- Cervix - Ectocervix
- 1.06
- Testis
- 0.91
Expression in transcripts per million
- Brain - Substantia nigra34.67
- Thyroid1.81
- Ovary1.07
- Cervix - Ectocervix1.06
- Testis0.91
- Adipose - Visceral (Omentum)0.7
- Lung0.7
- Cervix - Endocervix0.61
- Kidney - Medulla0.61
- Uterus0.59
- Brain - Hypothalamus0.5
- Vagina0.48
- Fallopian Tube0.48
- Bladder0.41
- Nerve - Tibial0.39
- Prostate0.3
- Artery - Coronary0.21
- Pituitary0.18
- Breast - Mammary Tissue0.17
- Artery - Aorta0.17
- Minor Salivary Gland0.17
- Small Intestine - Terminal Ileum0.15
- Artery - Tibial0.14
- Adipose - Subcutaneous0.13
- Spleen0.12
And 29 more, listed on the interactive page.
- GO:0015872
- GO:0051583
- GO:0090494
- GO:0005737
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0016600
- GO:0030424
- GO:0043005
- GO:0043025
- GO:0045121
- GO:0005330
- GO:0005515
- GO:0008504
parkinsonism
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: parkinsonism
Biological samples
- nervous system
PubMed 28216264dystonia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dystonia
Biological samples
- nervous system
PubMed 28216264increased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased locomotor activity
Biological samples
- nervous system
PubMed 28216264stereotypy
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: stereotypy
Biological samples
- nervous system
PubMed 28216264acne
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: acne
Biological samples
- nervous system
PubMed 28216264depression
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: depression
Biological samples
- nervous system
PubMed 28216264dyskinesia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dyskinesia
Biological samples
- nervous system
PubMed 28216264drug abuse/dependence
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: drug abuse/dependence
Biological samples
- nervous system
PubMed 28216264convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: convulsions
Biological samples
- nervous system
PubMed 28216264psychostimulation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: psychostimulation
Biological samples
- nervous system
PubMed 28216264decreased motor coordination
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased motor coordination
Biological samples
- nervous system
PubMed 28216264decreased motor strength
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased motor strength
Biological samples
- nervous system
PubMed 28216264
addictive psychostimulation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: addictive psychostimulation
Biological samples
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_TR_hDAT, is one of one assay component(s) measured or calculated from the NVS_TR_hDAT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceparkinsonism
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: parkinsonism
Biological samples
- central nervous system
PubMed 23197038dystonia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dystonia
Biological samples
- central nervous system
PubMed 23197038dyskinesia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dyskinesia
Biological samples
- central nervous system
PubMed 23197038depression
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: depression
Biological samples
- central nervous system
PubMed 23197038acne
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: acne
Biological samples
- central nervous system
PubMed 23197038seizures
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: seizures
Biological samples
- central nervous system
PubMed 23197038
Related records
Trials (1,267)
- "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
- [C-11]NPA PET-amphetamine in Cocaine Use Disorders
- 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
- 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression
- A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
- A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
- A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
- A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
- A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
- A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
- A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children
- A Comparative Study of KES524 in Patients With Obesity Disease
- A Comparison of Bupropion SR and Placebo for Smoking Cessation
- A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults
- A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder
- A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
- A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery
- A Dose Ranging Study of Modafinil for Methamphetamine Dependence
- A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With ADHD Compared to Healthy Adults
Drugs (45)
- Amitifadine Monoamine transporter inhibitor
- Amphetamine Dopamine transporter releasing agent
- Amphetamine adipate Dopamine transporter releasing agent
- Amphetamine aspartate Dopamine transporter releasing agent
- Amphetamine sulfate Dopamine transporter releasing agent
- Armodafinil Dopamine transporter inhibitor
- Bicifadine Monoamine transporter inhibitor
- Bupropion Dopamine transporter inhibitor
- Bupropion hydrobromide Dopamine transporter inhibitor
- Bupropion hydrochloride Dopamine transporter inhibitor
- Centanafadine Monoamine transporter inhibitor
- Dasotraline Monoamine transporter inhibitor
- Dexmethylphenidate Dopamine transporter inhibitor
- Dexmethylphenidate hydrochloride Dopamine transporter inhibitor
- Dextroamphetamine Dopamine transporter releasing agent
- Dextroamphetamine adipate Dopamine transporter releasing agent
- Dextroamphetamine saccharate Dopamine transporter releasing agent
- Dextroamphetamine sulfate Dopamine transporter releasing agent
- Diethylpropion Dopamine transporter inhibitor
- Diethylpropion hydrochloride Dopamine transporter inhibitor